These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24911439)

  • 1. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.
    Takeuchi H; Suzuki T; Remington G; Watanabe K; Mimura M; Uchida H
    J Clin Psychopharmacol; 2014 Aug; 34(4):517-20. PubMed ID: 24911439
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
    Yasui-Furukori N; Saito M; Nakagami T; Sugawara N; Sato Y; Tsuchimine S; Furukori H; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):537-40. PubMed ID: 20170699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
    Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia.
    Takeuchi H; Suzuki T; Remington G; Watanabe K; Mimura M; Uchida H
    Psychiatry Res; 2014 Aug; 218(1-2):244-6. PubMed ID: 24768247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
    Pérez-Iglesias R; Mata I; Martínez-García O; Garcia-Unzueta MT; Amado JA; Valdizán EM; Vázquez-Barquero JL; Crespo-Facorro B
    J Clin Psychopharmacol; 2012 Dec; 32(6):804-8. PubMed ID: 23131886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
    Lin CH; Kuo CC; Chou LS; Chen YH; Chen CC; Huang KH; Lane HY
    J Clin Psychopharmacol; 2010 Oct; 30(5):518-25. PubMed ID: 20814315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Watanabe K; Mimura M; Uchida H
    J Clin Psychiatry; 2014 Nov; 75(11):1209-14. PubMed ID: 25099201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
    Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
    Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone.
    Konarzewska B; Galińska-Skok B; Waszkiewicz N; Łazarczyk-Kirejczyk J; Malus A; Simonienko K; Szulc A
    Neuro Endocrinol Lett; 2014; 35(1):50-7. PubMed ID: 24625910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.
    Paslakis G; Deuschle M; Thome J; Rüsse S; Kopf D
    Pharmacopsychiatry; 2012 May; 45(3):96-9. PubMed ID: 22174030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
    Nakonezny PA; Byerly MJ; Rush AJ
    J Sex Marital Ther; 2007; 33(3):203-16. PubMed ID: 17454518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
    Yasui-Furukori N; Furukori H; Sugawara N; Tsuchimine S; Fujii A; Inoue Y; Kaneko S
    Hum Psychopharmacol; 2010 Apr; 25(3):236-42. PubMed ID: 20373475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction.
    Takeuchi H; Remington G
    Evid Based Ment Health; 2015 Nov; 18(4):117. PubMed ID: 26459470
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.
    Akhras KS; Singh J; Gopal S; Schadrack J; Palumbo JM
    Int J Clin Pract; 2009 Jun; 63(6):962-3; author reply 963. PubMed ID: 19490204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.